knowledge -WSS

knowledge

author：entertainment 2025-09-02 22:07:38 - browse：23

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： The aspartame in Diet Coke probably isn’t giving you cancer

entertainment

focus

WSS

Using force crossed my mind when examining a defiant young patient

Study fuels hope CAR

Medicare Advantage isn’t working — for anyone

Elisabeth Bik tackles the widespread issue of research misconduct

Virtual repurposing can help discover new uses for existing drugs

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

Swim instructor mom warns parents not to buy blue swimsuits for kids

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Beam, Prozac, "TechBio" and more

Affirmative action in medical school literally saved lives

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Hollywood unions extend contract negotiations for actors

Cholera vaccine supplies dangerously low, outbreaks surging

Heart attack and stroke risk calculators need revising

Parents surprise family after baby discharged from NICU after 170 days

focus

Cholera vaccine supplies dangerously low, outbreaks surging

Study fuels hope CAR

The U.S. needs a new definition of substance use “recovery”

Elisabeth Bik tackles the widespread issue of research misconduct

Color Health wants to make cancer screenings convenient

CDC panel: People 65 and older should get a Covid spring booster shot

hotspot

entertainment

focus

Wikipedia